PHARMACY2U LIMITED
Company number 03802593 · Monitor this company
This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.
Financial Health Score: C – Fair (Indicative Only)
This grade reflects the structural and compliance indicators visible in the registry data. The company is active, long-established, and its statutory filings are current, which are positive signs. However, the dataset provided does not include turnover, profit, asset, liability, or cash-flow figures, so profitability, liquidity, and solvency cannot be assessed. The score should therefore be read as a “structural check-up” rather than a full financial diagnosis.
1. Key Vital Signs
| Vital Sign | Reading | Interpretation |
|---|---|---|
| Company status | Active | The company is registered and not in liquidation, administration, or receivership. No obvious signs of acute distress. |
| Age / incorporation | Incorporated 8 July 1999 | Approximately 26 years old. An established trading history is generally favourable, like a long medical record. |
| Accounts category | Full | Full accounts have been filed; the company is not reporting as dormant or micro. |
| Last accounts made up to | 31 March 2025 | The most recent accounts are on record. |
| Accounts overdue? | No | Filing compliance is current; no late-account penalties indicated. |
| Confirmation statement | Last made up 7 July 2026; not overdue | Annual corporate “check-in” is up to date. |
| Share capital | £638,160.40 | A modest issued share capital. This is a baseline equity figure, not a measure of current cash or profitability. |
| Sector (SIC) | 47730 – Dispensing chemist in specialised stores | Regulated healthcare retail. Demand is typically defensive, but the sector involves inventory holding, NHS payment cycles, and compliance costs. |
| Ownership (PSCs) | P2u Holdings Limited: more than 75% of shares and voting rights; Bgf Gp Limited: between 25% and 50% as a member of a firm | Concentrated corporate ownership. A majority holder can provide stability and access to capital, but it also means control rests with a small number of corporate entities. |
| Board | Four current directors; one director resigned 11 September 2026 | Recent board change. Resignations can be routine, but a departure should be monitored to ensure continuity and no loss of key expertise. |
| Previous names | PHARMACY 2U LIMITED (until 11 March 2010) | A single historical rebrand; no unusual pattern of name changes. |
2. Symptoms Analysis
The available data shows no outward symptoms of acute distress: the company is active, filings are not overdue, and there is no indication of insolvency proceedings. However, the clinical picture is incomplete because the “internal chemistry” — the profit and loss account, balance sheet, and cash-flow statement — is not included in the data provided.
Specific observations:
- Missing financial metrics: Without revenue, gross profit, operating profit, current assets, current liabilities, or cash balances, it is impossible to calculate vital ratios such as the current ratio (ability to pay short-term debts), quick ratio, net margin, or operating cash flow. This is equivalent to observing a patient’s general appearance without blood tests or an ECG.
- Recent director resignation: A director stepped down on 11 September 2026. This is not, by itself, a sign of illness, but it is a change in governance that warrants attention to ensure the board remains fully functional.
- Concentrated ownership: With P2u Holdings Limited holding more than 75% of shares and voting rights, the company’s financial flexibility may be influenced by the parent’s strategy and funding decisions. Bgf Gp Limited’s 25–50% interest (as a member of a firm) suggests an additional institutional investor, which can be a source of support but also introduces shared control.
3. Diagnosis
Condition: Structurally stable, financially undiagnosed.
Based on the registry information alone, Pharmacy2U Limited appears to be a going concern with no formal insolvency proceedings and compliant filing behaviour. These are normal “vital signs” where they can be observed.
However, because no income statement, balance sheet, or cash-flow data was provided, a definitive diagnosis of financial wellness cannot be made. The company may be profitable and cash-generative, or it may be experiencing losses, cash burn, or working-capital pressure that is not visible from registry data. The prognosis is therefore guarded but not critical: the patient is conscious and mobile, but key internal tests have not yet been reviewed.
4. Recommendations
-
Obtain the latest full annual accounts
Request the balance sheet, profit and loss account, and cash-flow statement for the year ended 31 March 2025 (and any subsequent filings). These are the equivalent of blood tests and imaging; they are essential for a proper diagnosis. -
Calculate liquidity ratios
Once accounts are available, compute the current ratio (current assets ÷ current liabilities) and quick ratio to assess whether the company can meet obligations due within the next 12 months. -
Review operating cash flow
For a dispensing chemist, cash conversion is critical because of inventory holdings and NHS payment terms. Verify that the business generates cash from its core operations rather than relying on external funding. -
Assess dependence on the parent company
Given that P2u Holdings Limited holds more than 75% of shares and voting rights, determine whether the company depends on its parent for working capital, loans, or guarantees. -
Monitor board continuity
Following the resignation of a director on 11 September 2026, confirm that a replacement has been appointed or that the remaining directors can maintain effective decision-making. -
Prepare a 12-month cash-flow forecast
Model expected receipts (including NHS and private prescription income) against payments for stock, staff, premises, and tax. This will highlight any potential cash shortfalls before they become symptomatic. -
Maintain filing discipline
Continue to submit accounts and confirmation statements on time to avoid penalties and preserve the company’s credit standing with suppliers and lenders.